Journal of Pediatric Hematology/Oncology · 2009 · 12 citations · 28 references
MedicineOncologyPediatricsChemotherapyPediatric HematologyPediatric OncologyPediatric ChemotherapyPediatric LeukemiasAcute Leukemia ChemotherapyAcute Lymphoblastic Leukemia BiologyAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentPediatric Hematologic Malignancy ChemotherapyPrognostic Biomarkers
Treatment of children with acute lymphoblastic leukemia (ALL) is based on P-glycoprotein (P-gp)-dependent cytostatics. We assessed the P-gp function in blast cells as a possible prognostic factor and its influence on the overall survival. P-gp function was measured using the verapamil-sensitive Rhodamine efflux. Cell samples from 7 of 45 (16%) patients revealed rhodamine-efflux positive blasts. There were no relations between the presence of P-gp, clinical characteristics (age, sex, hepatomegaly, and splenomegaly) and initial laboratory parameters (immunophenotype, white blood cells count, and serum lactate dehydrogenase) in ALL. P-gp activity plays a negative role, both for a remission achieved on day 33 and for susceptibility to steroid therapy. Children bearing rhodamine-efflux positive blasts had a significantly shorter 5-year overall survival of 35%, as compared with 74% in those negative for P-gp function. Lack of any association with clinical characteristic and initial laboratory parameters suggests that presence of P-gp is an independent prognostic factor.
28